Keith S. Sultan
Advanced in Venous Thromboembolism (VTE)

Dr. Keith S. Sultan

Gastroenterology
125 Community Drive, Suite 100, 
Great Neck, NY 
On Staff At
Offers Telehealth
Advanced in Venous Thromboembolism (VTE)
125 Community Drive, Suite 100, 
Great Neck, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Keith Sultan is a Gastroenterologist in Great Neck, New York. Dr. Sultan is rated as an Advanced provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Viral Gastroenteritis, Ulcerative Colitis, Crohn's Disease, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Venous Thromboembolism (VTE).

Graduate Institution
State University Of NY At Stony Brook School Of Medicine
Residency
Northwell Health - Lenox Hill Hospital
Specialties
Gastroenterology
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine/Gastroenterology
Hospital Affiliations
North Shore University Hospital
Hofstra/Northwell School Of Medicine/Nursing
Long Island Jewish Medical Center
Plainview Hospital
Northwell Health Gastroenterology Institute
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Northwell Health Physician Partners Center for Advanced IBD Care
125 Community Drive, Suite 100, Great Neck, NY 11021

Additional Areas of Focus

Dr. Sultan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

66 Total Publications

Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease.
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease.
Journal: United European gastroenterology journal
Published: February 02, 2025
Similar Doctors
Advanced in Venous Thromboembolism (VTE)
Dr. Adam S. Faye
Gastroenterology
Advanced in Venous Thromboembolism (VTE)
Dr. Adam S. Faye
Gastroenterology

New York University

240 E 38th St, 
New York, NY 
 (6.6 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Faye is a Gastroenterologist in New York, New York. Dr. Faye is rated as a Distinguished provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Viral Gastroenteritis, Colitis, Ulcerative Colitis, Ileostomy, and Endoscopy.

Advanced in Venous Thromboembolism (VTE)
Dr. Samuel Cho
Gastroenterology
Advanced in Venous Thromboembolism (VTE)
Dr. Samuel Cho
Gastroenterology

Samuel Cho, M.D., P.C.

15011 Northern Blvd, 
Flushing, NY 
 (3.2 miles away)
718-460-9640
Languages Spoken:
English
See accepted insurances

Samuel Cho is a Gastroenterologist in Flushing, New York. Dr. Cho is rated as a Distinguished provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Chronic Erosive Gastritis, Indigestion, Gastritis, Spinal Fusion, and Laminectomy.

Advanced in Venous Thromboembolism (VTE)
Dr. Jonathan Rosenberg
Gastroenterology
Advanced in Venous Thromboembolism (VTE)
Dr. Jonathan Rosenberg
Gastroenterology

New York University

240 E 38th St, 
New York, NY 
 (6.6 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Rosenberg is a Gastroenterologist in New York, New York. Dr. Rosenberg is rated as a Distinguished provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Muscle Invasive Bladder Cancer, Diarrhea, Ileostomy, and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sultan's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile